Shionogi & Co., Ltd. - SGIOY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.99
▲ +0.12 (1.75%)

This chart shows the closing price for SGIOY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shionogi & Co., Ltd. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGIOY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGIOY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Shionogi & Co., Ltd. in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.99.

This chart shows the closing price for SGIOY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Shionogi & Co., Ltd.. This rating has held steady since April 2024, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/23/2023Sanford C. BernsteinInitiated CoverageUnderperform
12/8/2021Jefferies Financial GroupUpgradeHold ➝ Buy
3/31/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
3/23/2020Jefferies Financial GroupUpgradeHold ➝ Buy
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/26/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Shionogi & Co., Ltd. logo
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Read More

Today's Range

Now: $6.99
Low: $6.73
High: $7.25

50 Day Range

MA: $6.96
Low: $6.59
High: $7.36

52 Week Range

Now: $6.99
Low: $6.22
High: $9.11

Volume

315,389 shs

Average Volume

166,854 shs

Market Capitalization

$11.89 billion

P/E Ratio

11.91

Dividend Yield

1.64%

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Shionogi & Co., Ltd.?

The following Wall Street sell-side analysts have issued reports on Shionogi & Co., Ltd. in the last twelve months:
View the latest analyst ratings for SGIOY.

What is the current price target for Shionogi & Co., Ltd.?

0 Wall Street analysts have set twelve-month price targets for Shionogi & Co., Ltd. in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Shionogi & Co., Ltd. in the next year.
View the latest price targets for SGIOY.

What is the current consensus analyst rating for Shionogi & Co., Ltd.?

Shionogi & Co., Ltd. currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SGIOY.

What other companies compete with Shionogi & Co., Ltd.?

Other companies that are similar to Shionogi & Co., Ltd. include HOYA, Deutsche Post, Heineken, DENSO and Singapore Telecommunications. Learn More about companies similar to Shionogi & Co., Ltd..

How do I contact Shionogi & Co., Ltd.'s investor relations team?

Shionogi & Co., Ltd.'s physical mailing address is 3-1-8, Dosho-machi, Osaka Shi, Osaka Fu 541-0045. The company's listed phone number is (166) 202-2161. The official website for Shionogi & Co., Ltd. is www.shionogi.co.jp. Learn More about contacing Shionogi & Co., Ltd. investor relations.